Global Dog Vaccines Market Introduction and Overview
According to SPER Market Research, the Global Dog Vaccines Market is estimated to reach USD 3.79 billion by 2034 with a CAGR of 6.68%.
The report includes an in-depth analysis of the Global Dog Vaccines Market, including market size and trends, product mix, Applications, and supplier analysis.
The market for dog vaccines was valued at USD 2.12 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 6.68% between 2026 and 2030. The market is growing as a result of rising pet ownership and pet humanization, which encourages treating pets like members of the family and providing them with the finest comfort and care. Pet owners are more inclined to spend money on veterinary care and vaccinations since they view their animals as part of the family, which increases demand for both core and non-core vaccines. Pet humanization results in more knowledgeable pet owners who recognize the value of vaccination schedules and make sure dogs get the vaccinations they need on time.
Our in-depth analysis of the Global Dog Vaccines Market includes the following segments:
By Vaccine Type Insights
The modified live segment held the largest revenue share in 2024. The market for attenuated live vaccines is driven by their long-term immunity against illnesses. These vaccines protect against all parvoviruses and canine adenovirus-2. For instance, Nobivac, from Merck & Co, Inc, immunizes dogs against canine distemper virus, canine adenovirus type 1, canine parvovirus, and canine parainfluenza virus.
By Disease Type Insights
The canine infectious respiratory disease complex (CIRDC) segment generated the highest revenue in 2024. The presence of various causes for CIRDC has led to new vaccine development. For example, Merck Animal Health launched the Nobivac Intra-Trac Oral BbPi in September 2022, the first oral vaccine for Bordetella bronchiseptica and canine parainfluenza virus. Controlling the spread of these diseases is vital for protecting dogs' respiratory health and preventing outbreaks.
By Route of Administration Insights
Injectables held the highest revenue share in 2024 as they are the most popular among doctors and pet owners due to their precise dose administration. MSD Animal Health introduced Nobivac Respira Bb in March 2021 to prevent Bordetella bronchiseptica. A single dose protects dogs for seven months after the initial course and for one year after the booster dose.
By Duration of Immunity Insights
The one-year segment had the largest revenue share in 2024. The vaccine offers a year of immunity to help prevent common infections without needing regular booster shots. This gives dog owners an easier option, likely boosting market growth. Most core vaccines for dogs provide immunity for about a year, requiring annual booster shots for continued protection.
By Component Insights
The combined vaccine segment had the largest revenue share in 2024 and is expected to grow quickly from 2025 to 2030. These vaccines protect against multiple diseases and reduce the number of shots needed for dogs. This convenience is likely to boost demand in the dog vaccine market by making vaccinations easier. Furthermore, using one vaccine lowers veterinary costs and is cheaper for pet owners than getting individual vaccines. Combined vaccines also lessen stress for dogs, encouraging timely vaccinations.
By Distribution Channel Insights
Hospital and clinic pharmacies held the largest market share in 2024. They are important for distributing vaccines, making them accessible to pet owners. These pharmacies often collaborate with suppliers to provide vaccines for diseases like rabies and parvovirus. They are usually part of veterinary hospitals and clinics, where professionals give the vaccines, ensuring proper handling and storage.
By Regional Insights
The global market for dog vaccines was dominated by North America in 2024. The area is home to a number of significant dog vaccination companies. Additionally, rising pet ownership rates and greater knowledge of pet preventative healthcare are major drivers of this market expansion.
Market Competitive Landscape:
Leading companies in this sector are using strategies including mergers and acquisitions, partnerships and collaborations, and the introduction of new products and trials to increase their revenue share. For instance, in June 2023, MebGenesis Inc. and Boehringer Ingelheim International GmbH collaborated to develop canine monoclonal antibodies. Similarly, in June 2022, Zoetis Services LLC acquired Basepaws Inc, likely expanding its line of precision animal health products. It is anticipated that these developments would lead to an increase in this market.
Recent Developments:
- The CSIC-developed vaccine against canine leishmaniasis, a recombinant vaccine to fight the parasite that causes skin ulcers and severe inflammation of the liver and spleen, was released by the Zendal group in March 2024.
- Merck & Co., Inc.'s ongoing commitment to rabies prevention was demonstrated in June 2024 when it launched the NOBIVAC NXT Rabies portfolio in Canada, which comprises NOBIVAC NXT Canine-3 Rabies and NOBIVAC NXT Feline-3 Rabies.
- Merck Animal Health released the first oral vaccination in September 2022 that targets Bordetella bronchiseptica and the para-influenza virus, two canine respiratory infections.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Vaccine Type, By Disease Type, By Route of Administration, By Duration of Immunity, By Component, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Boehringer Ingelheim International GmbH, Zoetis Services LLC, Merck & Co., Inc, Elanco, Hester Biosciences Limited, Virbac, Bioveta a.s, Brilliant Bio Pharma, Heska Corporation, Zendal Group. |
Key Topics Covered in the Report:
- Global Dog Vaccines Market Size (FY’2025-FY’2034)
- Overview of Global Dog Vaccines Market
- Segmentation of Global Dog Vaccines Market By Vaccine Type (Modified/ Attenuated Live, Inactivated, Other Vaccines)
- Segmentation of Global Dog Vaccines Market By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex, Canine Parvovirosis/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Other Diseases)
- Segmentation of Global Dog Vaccines Market By Route of Administration (Injectables, Intranasal, Oral)
- Segmentation of Global Dog Vaccines Market By Duration of Immunity (1 Year, 3 Year, Others)
- Segmentation of Global Dog Vaccines Market By Component (Combined Vaccines, Mono Vaccines)
- Segmentation of Global Dog Vaccines Market By Distribution Channel (Retail, E-Commerce, Hospital/Clinic Pharmacies)
- Statistical Snap of Global Dog Vaccines Market
- Expansion Analysis of Global Dog Vaccines Market
- Problems and Obstacles in Global Dog Vaccines Market
- Competitive Landscape in the Global Dog Vaccines Market
- Details on Current Investment in Global Dog Vaccines Market
- Competitive Analysis of Global Dog Vaccines Market
- Prominent Players in the Global Dog Vaccines Market
- SWOT Analysis of Global Dog Vaccines Market
- Global Dog Vaccines Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.2. Market segment analysis
2.1. Research data source
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
5. Market variable and outlook
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
6.1. Global Dog Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dog Vaccines Market
7. Global Dog Vaccines Market, By Vaccine Type (USD Million) 2025-2034
7.1. Modified/ Attenuated Live
7.2. Inactivated (Killed)
8. Global Dog Vaccines Market, By Disease Type (USD Million) 2025-2034
8.2. Canine Infectious Respiratory Disease Complex (CIRDC)
8.3. Canine Parvovirosis/ Parvovirus Disease
8.4. Canine Leptospirosis
8.6. Infectious Canine Hepatitis
9. Global Dog Vaccines Market, By Route of Administration (USD Million) 2025-2034
10. Global Dog Vaccines Market, By Duration of Immunity (USD Million) 2025-2034
11. Global Dog Vaccines Market, By Component (USD Million) 2025-2034
12. Global Dog Vaccines Market, By Distribution Channel (USD Million) 2025-2034
12.3. Hospital/Clinic Pharmacies
13. Global Dog Vaccines Market Forecast, 2025-2034 (USD Million)
13.1. Global Dog Vaccines Market Size and Market Share
14. Global Dog Vaccines Market, By Region, 2025-2034 (USD Million)
14.1.6. Rest of Asia-Pacific
14.3. Middle East and Africa
14.3.1. Kingdom of Saudi Arabia
14.3.2. United Arab Emirates
14.3.8. Rest of Middle-East and Africa
14.5.3. Rest of Latin America
15.1.2. Financial outlook
15.1.4. Recent developments
15.2. Boehringer Ingelheim International GmbH
15.2.2. Financial outlook
15.2.4. Recent developments
15.3.2. Financial outlook
15.3.4. Recent developments
15.4.2. Financial outlook
15.4.4. Recent developments
15.5.2. Financial outlook
15.5.4. Recent developments
15.6.2. Financial outlook
15.6.4. Recent developments
15.7. Hester Biosciences Limited
15.7.2. Financial outlook
15.7.4. Recent developments
15.8. Brilliant Bio Pharma
15.8.2. Financial outlook
15.8.4. Recent developments
15.9.2. Financial outlook
15.9.4. Recent developments
15.10.2. Financial outlook
15.10.4. Recent developments
16. Conclusion
17. List of Abbreviations
18. Reference Links